BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17094335)

  • 1. [Recommendations for the diagnosis and treatment of latent and active tuberculosis in patients with inflammatory joint diseases treated with tumour necrosis factor alpha inhibitors].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Acta Reumatol Port; 2006; 31(3):237-45. PubMed ID: 17094335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonist drugs].
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E; ;
    Rev Port Pneumol; 2006; 12(5):603-13. PubMed ID: 17117328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update.
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E
    Acta Reumatol Port; 2008; 33(1):77-85. PubMed ID: 18344925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors - March 2008 update.
    Fonseca JE; Lucas H; Canhão H; Duarte R; Santos MJ; Villar M; Faustino A; Raymundo E
    Rev Port Pneumol; 2008; 14(2):271-83. PubMed ID: 25966834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases for candidates for therapy with tumor necrosis factor alpha inhibitors--March 2008 update.
    Eurico Fonseca J; Lucas H; Canhão H; Duarte R; José Santos M; Villar M; Faustino A; Raymundo E;
    Rev Port Pneumol; 2008; 14(2):271-83. PubMed ID: 18564448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
    Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
    J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
    Diel R; Hauer B; Loddenkemper R; Manger B; Krüger K
    Pneumologie; 2009 Jun; 63(6):329-34. PubMed ID: 19517358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis.
    Inanc N; Aydin SZ; Karakurt S; Atagunduz P; Yavuz S; Direskeneli H
    J Rheumatol; 2009 Dec; 36(12):2675-81. PubMed ID: 19918035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience].
    Fonseca JE; Canhão H; Silva C; Miguel C; Mediavilla MJ; Teixeira A; Castelão W; Nero P; Bernardes M; Bernardo A; Mariz E; Godinho F; Santos MJ; Bogas M; Oliveira M; Saavedra MJ; Barcelos A; Cruz M; Santos RA; Maurício L; Rodrigues M; Figueiredo G; Quintal A; Patto JV; Malcata A; da Silva JC; Araújo D; Ventura F; Branco J; Queiroz MV;
    Acta Reumatol Port; 2006; 31(3):247-53. PubMed ID: 17094336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
    Theis VS; Rhodes JM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
    Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
    J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay.
    Dinser R; Fousse M; Sester U; Albrecht K; Singh M; Köhler H; Müller-Ladner U; Sester M
    Rheumatology (Oxford); 2008 Feb; 47(2):212-8. PubMed ID: 18208824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
    Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.
    Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA
    J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for latent tuberculosis in anti-TNF-α candidate patients in a high tuberculosis incidence setting.
    Saidenberg-Kermanac'h N; Semerano L; Naccache JM; Brauner M; Falgarone G; Dumont-Fischer D; Guillot X; Valeyre D; Boissier MC
    Int J Tuberc Lung Dis; 2012 Oct; 16(10):1307-14. PubMed ID: 22863801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area.
    Bonfiglioli KR; Ribeiro AC; Moraes JC; Saad CG; Souza FH; Calich AL; Bonfa E; Laurindo IM
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):905-11. PubMed ID: 25199003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.